Boston Scientific (BSX) Revenue — Quarter Ended Sep 30, 2025
Revenue increased compared to the same quarter a year earlier, while the sequential quarter showed minimal change. The filing context indicates higher sales across all major product categories.
Key takeaway
Quarter ended Sep 30, 2025 · FY2025 Q3
Revenue increased compared to the same quarter a year earlier, while the sequential quarter showed minimal change. The filing context indicates higher sales across all major product categories.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$5.1B
Revenue reported for this quarter.
Quarter-over-quarter
+0.1%
Change from the immediately preceding quarter.
Year-over-year
+20.3%
Change from the comparable year-ago quarter.
Trailing four quarters
$19.4B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2024 | $4.6B | +22.4% |
| Mar 31, 2025 | $4.7B | +20.9% |
| Jun 30, 2025 | $5.1B | +22.8% |
| Sep 30, 2025 | $5.1B | +20.3% |
Revenue performance
The reported revenue rose year over year, reflecting continued expansion. Both the MedSurg and Cardiovascular segments contributed to the increase.
Quarterly comparison
Compared with the immediately preceding quarter, revenue was essentially unchanged. Versus the same period one year ago, the revenue level was markedly higher.
What to watch
Monitor whether the revenue growth rate can be sustained in the coming quarters.